TY - JOUR
T1 - Whole lung lavage therapy for pulmonary alveolar proteinosis
T2 - A global survey of current practices and procedures
AU - Campo, Ilaria
AU - Luisetti, Maurizio
AU - Griese, Matthias
AU - Trapnell, Bruce C.
AU - Bonella, Francesco
AU - Grutters, Jan
AU - Nakata, Koh
AU - Van Moorsel, Coline H.M.
AU - Costabel, Ulrich
AU - Cottin, Vincent
AU - Ichiwata, Toshio
AU - Inoue, Yoshikazu
AU - Braschi, Antonio
AU - Bonizzoni, Giacomo
AU - Iotti, Giorgio A.
AU - Tinelli, Carmine
AU - Rodi, Giuseppe
N1 - Funding Information:
This survey was born as part of the project entitled EuPAPNet, funded by eRARE Research Programmes on Rare Diseases. We have the approval by our ethics committee regarding the whole EuPAPNet project. The international survey does not collect individual patient data, but averages data from all the participating centres.
Funding Information:
This study was supported by a grant from the European Union E-Rare JTC 2009: EuPAPnet.
Publisher Copyright:
© 2016 The Author(s).
PY - 2016/8/31
Y1 - 2016/8/31
N2 - Background: Whole lung lavage (WLL) is the current standard of care treatment for patients affected by pulmonary alveolar proteinosis (PAP). However, WLL is not standardized and international consensus documents are lacking. Our aim was to obtain a factual portrayal of WLL as currently practiced with respect to the procedure, indications for its use, evaluation of therapeutic benefit and complication rate. Methods: A clinical practice survey was conducted globally by means of a questionnaire and included 27 centers performing WLL in pediatric and/or adult PAP patients. Results: We collected completed questionnaires from 20 centres in 14 countries, practicing WLL in adults and 10 centers in 6 countries, practicing WLL in pediatric patients. WLL is almost universally performed under general anesthesia, with a double-lumen endobronchial tube in two consecutive sessions, with an interval of 1-2 weeks between sessions in approximately 50 % of centres. The use of saline warmed to 37 °C, drainage of lung lavage fluid by gravity and indications for WLL therapy in PAP were homogenous across centres. There was great variation in the choice of the first lung to be lavaged: 50 % of centres based the choice on imaging, whereas 50 % always started with the left lung. The choice of position was also widely discordant; the supine position was chosen by 50 % of centres. Other aspects varied significantly among centres including contraindications, methods and timing of follow up, use of chest percussion, timing of extubation following WLL and lung isolation and lavage methods for small children. The amount of fluid used to perform the WLL is a critical aspect. Whilst a general consensus exists on the single aliquot of fluid for lavage (around 800 ml of warm saline, in adults) great variability exists in the total volume instilled per lung, ranging from 5 to 40 liters, with an average of 15.4 liters/lung. Conclusions: This international survey found that WLL is safe and effective as therapy for PAP. However these results also indicate that standardization of the procedure is required; the present survey represents the a first step toward building such a document.
AB - Background: Whole lung lavage (WLL) is the current standard of care treatment for patients affected by pulmonary alveolar proteinosis (PAP). However, WLL is not standardized and international consensus documents are lacking. Our aim was to obtain a factual portrayal of WLL as currently practiced with respect to the procedure, indications for its use, evaluation of therapeutic benefit and complication rate. Methods: A clinical practice survey was conducted globally by means of a questionnaire and included 27 centers performing WLL in pediatric and/or adult PAP patients. Results: We collected completed questionnaires from 20 centres in 14 countries, practicing WLL in adults and 10 centers in 6 countries, practicing WLL in pediatric patients. WLL is almost universally performed under general anesthesia, with a double-lumen endobronchial tube in two consecutive sessions, with an interval of 1-2 weeks between sessions in approximately 50 % of centres. The use of saline warmed to 37 °C, drainage of lung lavage fluid by gravity and indications for WLL therapy in PAP were homogenous across centres. There was great variation in the choice of the first lung to be lavaged: 50 % of centres based the choice on imaging, whereas 50 % always started with the left lung. The choice of position was also widely discordant; the supine position was chosen by 50 % of centres. Other aspects varied significantly among centres including contraindications, methods and timing of follow up, use of chest percussion, timing of extubation following WLL and lung isolation and lavage methods for small children. The amount of fluid used to perform the WLL is a critical aspect. Whilst a general consensus exists on the single aliquot of fluid for lavage (around 800 ml of warm saline, in adults) great variability exists in the total volume instilled per lung, ranging from 5 to 40 liters, with an average of 15.4 liters/lung. Conclusions: This international survey found that WLL is safe and effective as therapy for PAP. However these results also indicate that standardization of the procedure is required; the present survey represents the a first step toward building such a document.
KW - Interstitial lung disease
KW - Pulmonary alveolar proteinosis
KW - Rare disease
KW - Whole lung lavage
UR - http://www.scopus.com/inward/record.url?scp=84984851009&partnerID=8YFLogxK
U2 - 10.1186/s13023-016-0497-9
DO - 10.1186/s13023-016-0497-9
M3 - Article
C2 - 27577926
AN - SCOPUS:84984851009
SN - 1750-1172
VL - 11
JO - Orphanet Journal of Rare Diseases
JF - Orphanet Journal of Rare Diseases
IS - 1
M1 - 115
ER -